GILD Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Gilead Sciences (NASDAQ: GILD)
›
Gilead Sciences (NASDAQ: GILD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 17,000 employees.
The shares were at 166.53 USD on 19 November 2026, up 36.6% over 52 weeks. Its 52-week range is 116.88 USD to 176.58 USD: the price is 5.7% below the high and 42.5% above the low.
Its market capitalisation is 206.55B USD. It pays a dividend yielding 1.94% (it pays out 43% of its earnings), against a median of 2.55% among the dividend payers in that peer group.
Gilead Sciences reports return on equity of 37.5%, an operating margin of 38.2% and revenue up 6.8% year over year.
Its debt exceeds its cash by 18.28B USD, a debt-to-equity ratio of 1.10. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 26 analysts cover the stock, with an average rating of Buy; their mean price target of 175.92 USD is 5.6% above the current price. The next earnings report is expected on 9 February 2027.